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Cognitive Impairment and Risk of All-Cause and Cardiovascular
Disease Mortality Over 20-Year Follow-up: Results From the BLSA
Ji An, MS;* Haibin Li, PhD;* Zhe Tang, MD;* Deqiang Zheng, PhD; Jin Guo, PhD; Yue Liu, MS; Wei Feng, MS; Xia Li, PhD; Anxin Wang, PhD;
Xiangtong Liu, PhD; Lixin Tao, PhD; Chengbei Hou, PhD; Feng Zhang, PhD; Xinghua Yang, PhD; Qi Gao, PhD; Wei Wang, PhD;
Xiuhua Guo, PhD; Yanxia Luo, PhD
Background-—Cognitive impairment may increase the risk of all-cause and cardiovascular disease (CVD) mortality. This study
examined the association between cognitive function and risk of all-cause and CVD mortality among the elderly in Beijing, China.
Methods and Results-—A total of 1996 participants aged ≥55 years at baseline were enrolled from the BLSA (Beijing
Longitudinal Study of Aging). Cognitive function was assessed using the Mini-Mental State Examination (MMSE), and
participants were categorized as: <18, 18 to 23, 24 to 27, and 28 to 30. Cox proportional hazard models were used to
estimate the association. Hazard ratio (HR) and 95% confidence interval (CI) were reported. During a 20-year follow-up, 1122
(56.21%) participants died, 478 (42.60%) of whom died of CVD. Compared with MMSE scores of 28 to 30, participants with
MMSE scores of <18 were independently associated with all-cause mortality (hazard ratio, 2.14; 95% confidence interval,
1.59–2.87; P<0.001) and CVD mortality (hazard ratio, 4.52; 95% confidence interval, 2.80–7.30, P<0.001). Each 5-point
decrease in MMSE score was associated with a 34% increased risk of all-cause mortality and a 56% increased risk of CVD
mortality. This relationship remained statistically significant after using the competing risk model to consider non-CVD death
as a competing risk event.
Conclusion-—Cognitive impairment measured by MMSE score was associated with elevated risk of all-cause and CVD mortality
among the elderly in Beijing, China. ( J Am Heart Assoc. 2018;7:e008252. DOI: 10.1161/JAHA.117.008252.)
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C ognitive impairment is a serious threat to health of theelderly in the context of the demographic aging process.
It imposes a significant public health burden and shortens the
survival of patients, especially in China, which is experiencing
the fastest growth in the elderly population.1 The number of
deaths attributable to dementia in China went up from
1.6 million in 1990 to 2.3 million in 2016.2 Most recent
epidemiological studies have reported an association between
cognitive impairment and increased risk of all-cause mortality,
with both mild and moderate-to-severe cognitive impairment
being predictors of all-cause mortality in older adults.3,4
However, to our knowledge, very few studies have examined
this relationship in China.5,6 Analysis of the association
between cognitive impairment and mortality in China is thus
worthy of further research.
Cognitive impairment has also been shown to be related
to cardiovascular disease (CVD). Cognitive impairment
predicts CVD events independently in addition to traditional
risk factors, such as hypertension, smoking, diabetes
mellitus, lipid abnormality, increasing age, overweight, and
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obesity.7,8 Several risk factors for CVD are also risk factors
for cognitive impairment.9 Patients with cognitive impair-
ment have the reduced ability to maintain medication
adherence and carry out self-care, thus increasing the risk
of CVD.10,11 However, the association between cognitive
impairment and mortality resulting from CVD is less clear.
Previous studies demonstrated that the baseline Mini-Mental
State Examination (MMSE) score was a significant predictor
of CVD mortality.12–14 Furthermore, a recent observational
cohort study among nondemented older adults indicated
that the association between low cognitive function test
scores and increased mortality appeared to be particularly
strong for death from CVD.15 Nevertheless, another study
reported that mild cognitive impairment showed no signif-
icant correlation with cardiovascular mortality when tested
in a multivariable model.16 To date therefore the results
have been inconsistent, and other possible confounding
factors unreported by previous studies require further
exploration.
The aim of the present study was to determine the
association between cognitive impairment as assessed by the
MMSE and risk of all-cause and CVD mortality among a
general population aged ≥55 years in Beijing, China.
Methods
Data Collection and Study Population
Data, analytical methods, and study materials will not be
made available to other researchers for purposes of
reproducing the results or replicating the procedure. This
secondary analysis used data from the BLSA (Beijing
Longitudinal Study of Aging), a community-based prospective
cohort study of 3257 Chinese people aged ≥55 years at
baseline conducted by the Beijing Geriatric Clinical and
Research Center, Xuanwu Hospital of Capital Medical
University (Beijing, China). The representative cohort of the
elderly population in Beijing was based on a 3-stage
stratified random-clustering sampling procedure.17 Three
districts representing the urban, suburban, and rural areas
of Beijing were selected to constitute the BLSA sample.
Around 10% of sampling data, including the distribution of
geography, age, and education of the study sample, were
obtained from the Fourth National Census Data.18 Follow-up
data from this cohort were based on self-reporting informa-
tion covering demographic characteristics, socioeconomic
status, functional abilities, lifestyle factors, medications,
physical health including diseases, psychological health, and
cognitive status (eg, the MMSE).19
Because of missing data, a total of 1996 participants (978
men and 1018 women) followed up from 1992 to 2012 were
finally recruited for the analysis, and the self-reported
information was compiled every 2 to 3 years. Written
informed consent was obtained from all participants, and
ethics approval was provided by the ethics committee of
Xuanwu Hospital, Capital Medical University.
Outcome Measures
The main outcome was death from all causes and CVD
occurring between August 1992 and December 2012.
Death from CVD was classified according to the ninth or
tenth International Classification of Disease (ICD-9 or ICD-
10). Survival status was obtained from interviews with
family members or relatives when family members were
unavailable. The information was verified by household
registration records and death records. For the final
analysis, non-CVD death was considered as a competing
event.
Assessment of Cognitive Function
Cognitive function was assessed using the MMSE, a widely
used screening test. MMSE score ranges from 0 to 30 and
consists of different cognitive domains, with a higher MMSE
score indicating better cognitive function. Baseline MMSE
scores were categorized into 4 groups: <18, 18 to 23, 24 to
27, and 28 to 30 (reference). The standard cut-off score of
≥28 is generally considered normal cognition, and scores of
<24 and <18 were used to identify individuals with sus-
pected mild cognitive impairment and severe cognitive
impairment.9,14 Education adjusted MMSE cut-off scores
were also used to classify participants as cognitively impaired
or unimpaired. Cut-off scores were 25 for uneducated
participants, 27 for those with primary school education
Clinical Perspective
What Is New?
• Baseline cognitive impairment measured by the Mini-Mental
State Examination was associated with an increased risk of
all-cause and cardiovascular disease mortality among
community-dwelling older Chinese people.
• The relationship between cognitive impairment and cardio-
vascular disease mortality were robust after using the
competing risk model considering non–cardiovascular dis-
ease death as a competing event rather than censors.
What Are the Clinical Implications?
• Screening for cognitive impairment by using the Mini-Mental
State Examination has important value in predicting risk of
all-cause and cardiovascular disease mortality in the elderly
population.
DOI: 10.1161/JAHA.117.008252 Journal of the American Heart Association 2
Cognitive Impairment and Mortality An et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on October 23, 2018
levels, and 29 for participants with secondary school or above
education levels.20
Assessment of Potential Confounding Variables
At baseline, variables, including demographics characteristics,
lifestyle factors, heath conditions, and medication, were
collected using a face-to-face standardized questionnaire by
trained researchers (mainly by physicians or nurses). Detailed
measurement and classification of each variable have been
reported in previous studies.17 Education level was catego-
rized as uneducated, primary school graduates (≥6 years of
education), and secondary school graduates and above
(≥9 years of education). Participants were classified as a
frequent exercise group if they self-reported exercising almost
every day. Marital status was divided into 2 groups: married
and single. The single group included separated, widowed,
divorced, and those who remained unmarried. Region was
categorized as: rural, suburban, and urban. Both cigarette
smoking status and alcohol consumption were assessed using
questions and were divided into 3 categories: never, former,
and current.
According to height and weight of participants, body mass
index was calculated as weight in kilograms divided by the
square of height in meters (kg/m2). Physical impairment was
assessed using the Activities of Daily Living and Instrumental
Activities of Daily Living.18 Participants were divided into
complete ability or disability group based on Activities of
Daily Living ADL and Basic Activities of Daily Living,
respectively. We measured depressive symptoms using the
20-item version of the Centre for Epidemiological Studies
Depression Scale.
Blood pressure was measured twice on the right arm in a
sitting position by a trained nurse, with at least a 5-minute
interval. All blood samples were collected after overnight
fasting for at least 12 hours. Fasting plasma glucose, total
cholesterol, high-density lipoprotein cholesterol, and low-
density lipoprotein cholesterol were measured. Hypertension
was defined as systolic BP ≥140 mm Hg or diastolic BP
≥90 mm Hg or regular use of antihypertensive medication.
Diabetes mellitus was defined as an fasting plasma glucose
level ≥7.0 mmol/L or regular use of antidiabetic drugs.
Dyslipidemia was diagnosed as a serum total cholesterol
level ≥5.17 mmol/L, or low-density lipoprotein cholesterol
≥3.62 mmol/L, or high-density lipoprotein cholesterol
≤1.04 mmol/L, or regular use of antihyperlipidemia medica-
tions. Hypertension, diabetes mellitus, and dyslipidemia were
also identified according to a self-reported history of diagnosis.
Medical history of CVD, chronic obstructive pulmonary disease,
and arthritis were determined by using a physician-based
questionnaire. Medication was obtained directly from prescrip-
tion bottles.
Statistical Analysis
We divided participants into 4 groups according to the
conventional MMSE cut-off values. MeanSD was calculated
for continuous variables and frequency (percentage) for cate-
gorical variables. Comparisons between participants in different
MMSE score categories were performed using ANOVA for
continuous variables and the v2 test for categorical variables.
Kaplan–Meier curves were generated to plot the unadjusted
survival estimates according to baseline MMSE category, and
the log-rank test was used to compare survival curves.
We used Cox proportional hazard models to estimate the
association between MMSE score and risk of all-cause and
CVD mortality. The group with an MMSE of 28 to 30 was used
as the reference category in the Cox regression models.
Hazard ratio (HR) and 95% confidence interval (CI) were
reported. Several models were built: Model 1 was an
unadjusted model; model 2 was adjusted for age and sex;
model 3 was adjusted for the covariates in model 2 adding
exercise, alcohol consumption, smoking status, education
level, marital status, and region; and model 4 was adjusted for
the covariates in model 3 adding body mass index, physical
impairment, depression, medical history (CVD, hypertension,
diabetes mellitus, dyslipidemia, chronic obstructive pulmonary
disease, and arthropathy), and medications (for CVD, chronic
obstructive pulmonary disease, and analgesics). We also
estimated risk of all-cause and CVD mortality associated with
the MMSE score per 5-unit change in the above 4 Cox
proportional hazard models. According to past knowledge,
age and sex were important risk factors in the relationship
between cognitive function and mortality.15 Therefore, sub-
group analysis was performed by stratifying the study
participants according to age (<65 and ≥65) and sex (male
and female) in the fully adjusted model to explore whether
male and female and younger and older individuals differ in
the relationship. Interactions between baseline MMSE and
subgroup variables were tested. Additionally, sensitivity
analysis was conducted by using the competing risk model.
We utilized the multivariable model to adjust for the risk
estimates of non-CVD death as a competing risk. To further
confirm the stability of results, we used education-adjusted
MMSE cut points (25, 27, and 29 for participants with
uneducated, primary school, and secondary school or above
education levels) to evaluate the relationship between cogni-
tive impairment and risk of all-cause and CVD mortality,
adjusted for all covariates.20 We also assessed the associa-
tion between MMSE scores and risk of all-cause and CVD
mortality in people without history of CVD in order to reduce
the potential bias for CVD mortality. Data analysis was
conducted using SAS software (version 9.4; SAS Institute,
Cary, NC). All statistical tests were 2-sided, and P values
<0.05 were considered statistically significant.
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Results
Baseline Characteristics
In the current analysis, 1996 participants (978 men and 1018
women) who completed the baseline MMSE were enrolled
during a median follow-up period of 8.00 years (interquartile
range, 5.00–14.65). Mean age (SD) of the population was
69.028.47 years. Median MMSE score was 24 (interquartile
range, 21–26) and ranged from 3 to 30. Participants with
reduced MMSE were older, more women than men; had a
lower proportion of receiving education; were less likely to
marry, exercise, and live in an urban area; had a lower
baseline body mass index and lower rates of CVD; had higher
rates of physical impairment, depression, and hypertension;
and were less likely to use CVD medications (Table 1).
MMSE and All-Cause Mortality
On follow-up, a total of 1122 (56.21%) participants died of any
cause among the overall study population (Table 2). Figure 1
shows the Kaplan–Meier unadjusted survival estimates for
different MMSE categories. A log-rank test revealed a
significant difference in the 4 groups (v2=202.10; P<0.001).
All-cause mortality risk was elevated in parallel with a
decrease in MMSE (Table 2). In the univariate Cox model,
participants with reduced MMSE scores showed a graded
increased risk of all-cause mortality compared with MMSE
scores of 28 to 30 (MMSE <18 [unadjusted HR, 3.73; 95% CI,
2.95–4.71; P<0.001]). After accounting for age and sex
(model 2), demographic characteristics, and lifestyle factors
(model 3), we found similar associations between MMSE
score and risk of all-cause mortality. In the fully adjusted
multivariable model, with further adjustment for functional
abilities, physical health, and medications, participants with
MMSE scores of 24 to 27 (HR, 1.12; 95% CI, 0.90–1.38;
P=0.322), 18 to 23 (HR, 1.44; 95% CI, 1.14–1.83; P=0.003),
and <18 (HR, 2.14; 95% CI, 1.59–2.87; P<0.001) also had a
graded all-cause mortality risk compared with MMSE scores
of 28 to 30. We also discovered that each 5-point decrease in
MMSE score was associated with a 34% increased risk of
mortality in the fully adjusted model (Table 2).
MMSE and Cardiovascular Disease Mortality
During a 20-year follow-up, 478 (42.60%) of the 1122
(56.21%) documented deaths were attributed to CVD
(Table 2). Figure 2 shows the Kaplan–Meier unadjusted
survival estimates for different MMSE categories. A log-rank
test revealed a significant difference in the 4 groups
(v2=140.36; P<0.001). CVD mortality risk was also elevated
in relation to cognitive decline (Table 2). In the univariate Cox
model, participants with reduced MMSE scores showed a
graded increased risk of CVD mortality compared with MMSE
scores of 28 to 30 (MMSE <18 [unadjusted HR, 6.22; 95% CI,
4.22–9.17; P<0.001]). After accounting for age and sex
(model 2), demographic characteristics, and lifestyle factors
(model 3), similar associations were found between MMSE
score and risk of CVD mortality. In a fully adjusted model,
participants with MMSE scores of 24 to 27 (HR, 1.67; 95% CI,
1.15–2.44; P=0.008), 18 to 23 (HR, 2.54; 95% CI, 1.69–3.82;
P<0.001), and <18 (HR, 4.52; 95% CI, 2.80–7.30; P<0.001)
had a graded increase in risk of CVD mortality compared with
MMSE scores of 28 to 30. We also investigated each 5-point
decrease in MMSE score, which was associated with a 56%
increased risk of CVD mortality in the fully adjusted model
(Table 2).
Subgroup Analysis
Subgroup analysis was followed by stratification of the
population by age and sex. The reduced baseline MMSE
score associated with increased risk of all-cause and CVD
mortality was similar in those younger or older than 65 years,
whether male or female. The analysis stratified by age
revealed that compared with MMSE scores of 28 to 30,
participants aged ≥65 years in the lowest MMSE group had a
2.96-fold (95% CI, 2.12–4.15) greater risk of all-cause
mortality and a 4.73-fold (95% CI, 2.74–8.16) greater risk of
CVD mortality. Furthermore, participants aged <65 years in
the lowest MMSE group had a 1.73-fold (95% CI, 0.83–3.60)
greater risk of all-cause mortality and a 7.16-fold (95% CI,
2.47–20.76) greater risk of CVD mortality (Table 3). We did
not find a significant interaction between MMSE scores and
age for both all-cause and CVD mortality (P>0.05 for
interaction; Table 3).
The analysis stratified by sex revealed that male subjects in
the lowest MMSE group versus the highest MMSE group were
associated with a 2.96-fold (95% CI, 1.84–4.75) greater risk of
all-cause mortality and a 5.03-fold (95% CI, 2.51–10.06)
greater risk of CVD mortality. Furthermore, female subjects in
the lowest MMSE group versus the highest MMSE group had a
1.44-fold (95% CI, 0.86–2.40) greater risk of all-cause
mortality and a 5.62-fold (95% CI, 1.97–16.00) greater risk
of CVD mortality (Table 4). In addition, sex was a significant
(P=0.037 for interaction) modifier of the association between
MMSE scores and all-cause mortality (Table 4).
Sensitivity Analysis
By using the competing risk model, each 5-point decrease in
baseline MMSE score was associated with a 36% increased
risk of CVD mortality (HR, 1.36; 95% CI, 1.18–1.57). In the
fully adjusted multivariable analysis, the association between
participants with MMSE scores of 24 to 27 (HR, 1.56; 95% CI,
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Table 1. Baseline Characteristics of the Study Population
Characteristic
Baseline MMSE Score
P Value<18 18 to 23 24 to 27 28 to 30
No. of subjects 193 772 710 321 
Age (mean; SD), y 75.45 (8.28) 70.25 (8.05) 67.40 (8.29) 65.79 (7.24) <0.001
BMI (mean; SD), kg/m2 22.30 (4.09) 22.78 (4.01) 23.63 (3.93) 24.42 (3.66) <0.001
Female, n (%) 158 (81.87) 479 (62.05) 280 (39.44) 101 (31.46) <0.001
Education level, n (%) <0.001
Uneducated 185 (95.85) 595 (77.07) 230 (32.39) 32 (9.97)
Primary school 7 (3.63) 150 (19.43) 308 (43.38) 106 (33.02)
Secondary
school or above
1 (0.52) 27 (3.50) 172 (24.23) 183 (57.01)
Frequent exercise,
n (%)
83 (43.01) 426 (55.18) 454 (63.94) 223 (69.47) <0.001
Married, n (%) 82 (42.49) 447 (57.90) 545 (76.76) 268 (83.49) <0.001
Region, n (%) <0.001
Rural 56 (29.02) 147 (19.04) 76 (10.70) 14 (4.36)
Suburban 69 (35.75) 268 (34.72) 151 (21.27) 32 (9.97)
Urban 68 (35.23) 357 (46.24) 483 (68.03) 275 (85.67)
Smoking status, n (%) <0.001
Never 136 (70.47) 448 (58.03) 329 (46.34) 170 (52.96)
Former 25 (12.95) 104 (13.47) 136 (19.15) 58 (18.07)
Current 32 (16.58) 220 (28.50) 245 (34.51) 93 (28.97)
Alcohol consumption, n (%) <0.001
Never 154 (79.79) 562 (72.80) 461 (64.93) 218 (67.91)
Former 11 (5.70) 66 (8.55) 55 (7.75) 29 (9.03)
Current 28 (14.51) 144 (18.65) 194 (27.32) 74 (23.05)
Depression, n (%) 48 (25.13) 171 (22.24) 105 (14.85) 35 (10.90) <0.001
Physical impairment
IADL, n (%) 114 (59.07) 280 (36.27) 96 (13.52) 29 (9.03) <0.001
ADL, n (%) 19 (9.84) 44 (5.70) 11 (1.55) 2 (0.62) <0.001
Medical history
CVD, n (%) 30 (15.54) 141 (18.26) 142 (20.00) 84 (26.17) 0.009
Hypertension,
n (%)
134 (69.43) 506 (65.54) 425 (59.86) 187 (58.26) 0.009
Diabetes mellitus,
n (%)
19 (9.84) 92 (11.92) 81 (11.41) 43 (13.40) 0.657
Dyslipidemia, n (%) 135 (69.95) 453 (58.68) 438 (61.69) 211 (65.73) 0.013
COPD, n (%) 18 (9.33) 94 (12.18) 98 (13.80) 44 (13.71) 0.356
Arthritis, n (%) 14 (7.25) 50 (6.48) 48 (6.76) 17 (5.30) 0.795
Medications
CVD, n (%) 21 (10.88) 101 (13.08) 102 (14.37) 70 (21.81) 0.001
COPD, n (%) 16 (8.29) 74 (9.59) 57 (8.03) 22 (6.85) 0.474
Analgesics, n (%) 19 (9.84) 80 (10.36) 60 (8.45) 13 (4.05) 0.008
ADL indicates Activities of Daily Living; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; IADL, Instrumental Activities of Daily Living;
MMSE, Mini-Mental State Examination.
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1.08–2.26), 18 to 23 (HR, 2.32; 95% CI, 1.56–3.44), and <18
(HR, 3.34; 95% CI, 2.07–5.40) and a graded increase in the
risk of CVD mortality was statistically significant (Figure 3).
Moreover, after using education adjusted MMSE scores to
derive groups, participants with cognitive impairment was
associated with a 61% increased risk of CVD mortality (HR,
1.61; 95% CI, 1.23–2.10) compared with cognitively normal
participants (Table S1). In addition, the sample size was
limited to 1599 after excluding participants with history of
CVD. Baseline MMSE scores of <18 was also associated with
a 2.20-fold (95% CI, 1.57–3.07) greater risk of all-cause
mortality and a 5.02-fold (95% CI, 2.80–8.98) greater risk of
CVD mortality compared with MMSE of 28 to 30 among
participants without CVD at baseline (Table S2).
Discussion
The present study showed that baseline cognitive impairment
measured by MMSE score was associated with an elevated
risk of all-cause and CVD mortality among a population of the
BLSA. Moreover, the association between MMSE score and
risk of CVD mortality remained highly significant in the
competing risk model in fully multivariable analysis.
Most recent population-based epidemiological studies
have extensively reported a consistent association between
cognitive impairment and increased risk of all-cause mortality
in the elderly, and MMSE score as a common measure of
cognitive impairment has been a powerful and independent
predictor of all-cause mortality.4,7,16,21 To the best of our
knowledge, only 2 studies have examined the relationship
between baseline cognitive function and mortality in China.5,6
Gao et al indicated that baseline cognitive function assessed
by composite cognitive z-score predicts future mortality
incidence among a rural Chinese cohort aged ≥65 years.6
An and Liu showed that baseline cognitive impairment
measured using the MMSE was inversely associated with
longevity, although the population was confined to the oldest
Chinese aged ≥80 years.5 The results of our study are
consistent with the findings from previous literature, given
that we found that impairment in cognitive function increased
the risk of all-cause death over a 20-year follow-up in a
population aged ≥55 years in Beijing.
Recent studies reported the relationship between cognitive
impairment and CVD. Indeed, it has been suggested that
cognitive impairment provides predictive value for CVD,
although the underlying pathological mechanisms of any
correlations are less clear.7,8 The accumulating evidence in
support of the association between cognitive impairment and
CVD led to formulation of the hypothesis that MMSE score
might also provide additional predictive value for CVD
Table 2. Hazard Ratios (95% CI) for All-Cause and Cardiovascular Disease Mortality According to Baseline MMSE Score (n=1996)
MMSE Score Participants (No.) Death (No.), n (%)
Hazard Ratio (95% CI)*
Model 1† Model 2‡ Model 3§ Model 4k
All-cause mortality
Decreased by 5 points 1996 1122 (56.21) 1.69 (1.58–1.81)¶ 1.50 (1.39–1.62) 1.38 (1.26–1.52)¶ 1.34 (1.22–1.47)¶
MMSE <18 193 130 (40.50) 3.73 (2.95–4.71)¶ 2.77 (2.14–3.58)¶ 2.16 (1.61–2.89)¶ 2.14 (1.59–2.87)¶
MMSE 18 to 23 772 327 (46.06) 2.04 (1.68–2.47)¶ 1.84 (1.50–2.24)¶ 1.49 (1.17–1.88)# 1.44 (1.14–1.83)#
MMSE 24 to 27 710 509 (65.93) 1.20 (0.98–1.47) 1.20 (0.98–1.47) 1.07 (0.86–1.33) 1.12 (0.90–1.38)
MMSE 28 to 30 321 156 (80.83) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Cardiovascular disease mortality
Decreased by 5 points 1996 478 (23.95) 1.84 (1.67–2.04)¶ 1.81 (1.61–2.03)¶ 1.59 (1.39–1.82)¶ 1.56 (1.36–1.79)¶
MMSE <18 193 38 (11.84) 6.22 (4.22–9.17)¶ 5.98 (3.93–9.10)¶ 4.37 (2.72–7.01)¶ 4.52 (2.80–7.30)¶
MMSE 18 to 23 772 135 (19.01) 3.06 (2.17–4.31)¶ 3.13 (2.20–4.46)¶ 2.51 (1.68–3.76)¶ 2.54 (1.69–3.82)¶
MMSE 24 to 27 710 226 (29.27) 1.69 (1.18–2.42)# 1.72 (1.20–2.47)# 1.56 (1.07–2.28)# 1.67 (1.15–2.44)#
MMSE 28 to 30 321 79 (40.93) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
CI indicates confidence interval; MMSE, Mini-Mental State Examination.
*Hazard ratio (95% CI) was calculated from Cox models.
†
Unadjusted model.
‡
Age- and sex-adjusted model.
§
Adjusted for age, sex, exercise, alcohol consumption, smoking status, education level, marital status, and region.
k
Adjusted for age, sex, exercise, alcohol consumption, smoking status, education level, marital status, region, body mass index (BMI), physical impairment, depression, medical history
(cardiovascular disease [CVD], hypertension, diabetes mellitus, dyslipidemia, chronic obstructive pulmonary disease [COPD], arthropathy), and medications (for CVD, COPD, and
analgesics).
¶
P<0.001.
#
P<0.05.
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mortality.16 In addition, based on the results of the associ-
ation between cognitive impairment and mortality risk, some
investigators assessed the association with cause-specific
mortality, and 1 study showed that the association of low
cognitive function with increased mortality appeared to be
particularly strong for death from CVD.15 Nevertheless,
available data from previous studies on the association
between cognitive impairment and CVD mortality in the
elderly are controversial. Several recent studies have sug-
gested that worse cognitive function, as measured by various
cognitive tests, is related to the risk of CVD mortality.12,13,15
Regarding the use of the MMSE to assess cognitive function,
an analysis of the ONTARGET (ONgoing Telmisartan Alone and
in Combination With Ramipril . . . Alone and combination with
Ramipril global Endpoint trial) and TRANSCEND (Telmisartan
Random- ized Assessment Study in ACE-Intolerant Subjects
with Cardiovascular Disease) trials reported that baseline
MMSE score was a significant predictor of cardiovascular
mortality among the population of patients at high risk for
CVD.7 However, a previous study demonstrated that mild
cognitive impairment was associated with cardiovascular
mortality only when studied separately or in a sex- and age-
adjusted model, whereas in a multivariable model the MMSE
score lost its significance.16 Our findings were coincident with
the relationship in the unadjusted model and sex- and age-
adjusted model, but in multivariable models, which have not
generally been related to cognitive impairment, findings were
discrepant: Cognitive impairment was associated with risk of
CVD mortality. Finally, after using the competing risk model
that considers non-CVD death as competing events or
excluding those participants with a history of CVD, the
relationship between reduced MMSE score and increased
CVD mortality risk was still statistically significant, although
further research to confirm the stability of these results is
warranted.
According to our findings, the association of participants
with MMSE scores of 24 to 27 was not statistically significant
for all-cause mortality given that this MMSE category was
expected to be close to normal status. However, baseline
MMSE had a strong and significant association with CVD
mortality in this population. Our study examined the
relationship in community-dwelling older Chinese people
from the BLSA, who were recruited in 1992. Because of the
cultural background, more than 50% of the participants had
less than 6 years of formal education. Cultural background
had an influence on MMSE performance, and education is
closely related to cultural background.22 MMSE scores
generally decline with advancing age and can be biased by
Figure 1. Kaplan–Meier Curve for hazard of all-cause death by the baseline Mini-Mental State
Examination (MMSE) score.
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baseline educational level and language.23 Therefore, study
sample in BLSA, which comprised a more-uneducated elderly
population than previous studies, may contribute to the
strong association of MMSE and CVD mortality risk.
Additionally, the relationship between early cognitive impair-
ment assessed by education-adjusted MMSE cut point
remained statistically significant and further confirmed the
stability of our results.
To reduce the possibility that observed associations were
confounded, we added variables that have been previously
reported to be confounding factors into the regression model.
In our analysis, we adjusted for age and sex in model 2 and
demographic characteristics and lifestyle in model 3 because
these factors were common potential confounders between
cognitive function and mortality risk.7,12 In addition to
common factors, we were able to adjust for physical health
and medications in model 4 that may also confound the
relationship. These variables have been shown to increase the
risk of CVD or mortality risk and were associated with
cognitive impairment.24 Furthermore, previous studies
reported that depression often coexisted with cognitive
impairment among elderly individuals and appeared to
increase all-cause as well as cardiovascular mortality.14
Therefore, we also evaluated the influence of depressive
symptoms in model 4. With reduced MMSE scores at
baseline, most confounding factors were more prevalent in
participants and adjustment for them might also play a role in
the downward trend from model 1 to model 4. Whereas
adjustment for age, sex, physical impairment, depression,
medical history, and medications had only a very modest
influence on the magnitude of the HR, in model 3 we found a
more-obvious attenuation of the magnitude of association
between baseline MMSE score and mortality after adding
education, marital status, region, and lifestyle factors to the
models.
The findings of previous studies on sex differences
between cognitive function and mortality have been
inconsistent.5,15,25 Perna et al showed that the association
between low COGTEL (Cognitive Telephone Screening Instru-
ment) total scores and all-cause mortality was much stronger
among men than in women.15 Another study using the same
cognitive testing revealed a contrasting pattern: The
researchers found no evidence of differential impact of
baseline cognitive impairment on mortality between sexes,
although the cohort consisted of the oldest-old Chinese.5 In
the present study, we found that males with reduced MMSE
score had a higher risk of all-cause mortality than females,
and there was an interaction between sex and all-cause
Figure 2. Kaplan–Meier Curve for hazard of CVD death by the baseline Mini-Mental State Examination
(MMSE) score. CVD indicates cardiovascular disease.
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mortality (P=0.037 for interaction). This may be attributed to
more-traditional lifestyle risk factors among men than women,
such as smoking, drinking, and physical inactivity, which
contribute to both cognitive impairment and all-cause
mortality.26 However, women were more sensitive to the
relationship between MMSE and CVD mortality. This may be
caused by particularity of women. Elderly women show an
increased risk of CVD attributed to aging, less physically
active, emotional disorders, and estrogen deprivation at time
of menopause.27,28 Moreover, scores for very elderly people
may be influenced by external variation, and the very old who
survive the study period may represent a different population
from those who have previously died.29 When we analyzed the
association stratified by age, the 95% CIs of sex-specific
estimates were also widely overlapping and participants aged
>65 years were more sensitive to the association with
reduced MMSE scores. The differences we observed between
younger and older subgroups may also be caused by higher
all-cause mortality rate and lower CVD mortality rate in older
subgroups as a result of the failure of traditional age-related
CVD risk markers.16
Our study has several strengths, including the large
number of deaths from all causes and CVD disease during a
20-year follow-up period, while considering competing risk to
Table 3. Hazard Ratios (95% CI) of All-Cause and CVD Mortality Stratified Analysis by Age (Dichotomized Into <65 and ≥65 Years)
MMSE Score
Age <65 (n=701) Age ≥65 (n=1295)
P for InteractionNo. Hazard Ratio (95% CI) No. Hazard Ratio (95% CI)
All-cause mortality 0.453
MMSE <18 25 1.73 (0.83–3.60) 168 2.96 (2.12–4.15)*
MMSE 18 to 23 208 1.27 (0.81–2.01) 564 1.67 (1.26–2.22)*
MMSE 24 to 27 315 0.86 (0.58–1.28) 395 1.33 (1.02–1.73)†
MMSE 28 to 30 153 1 (Reference) 168 1 (Reference)
CVD mortality 0.587
MMSE <18 25 7.16 (2.47–20.76)† 168 4.73 (2.74–8.16)*
MMSE 18 to 23 208 3.13 (1.34–7.29)† 564 2.47 (1.54–3.96)*
MMSE 24 to 27 315 2.10 (0.96–4.59) 395 1.57 (1.01–2.45)†
MMSE 28 to 30 153 1 (Reference) 168 1 (Reference)
Adjusted for sex, exercise, alcohol consumption, smoking status, education level, marital status, region, body mass index, physical impairment, depression, medical history, and
medications by multivariate Cox models. CVD indicates cardiovascular disease; CI, confidence interval; MMSE, Mini-Mental State Examination.
*P<0.001.
†
P<0.05.
Table 4. Hazard Ratios (95% CI) of All-Cause and CVD Mortality Stratified Analysis by Sex
MMSE Score
Female (n=1018) Male (n=978)
P for InteractionNo. Hazard Ratio (95% CI) No. Hazard Ratio (95% CI)
All-cause mortality 0.037
MMSE <18 158 1.44 (0.86–2.40) 35 2.96 (1.84–4.75)*
MMSE 18 to 23 479 1.04 (0.65–1.67) 293 1.57 (1.18–2.09)†
MMSE 24 to 27 280 0.81 (0.52–1.26) 430 1.21 (0.94–1.56)
MMSE 28 to 30 101 1 (Reference) 220 1 (Reference)
CVD mortality 0.141
MMSE <18 158 5.62 (1.97–16.00)† 35 5.03 (2.51–10.06)*
MMSE 18 to 23 479 3.22 (1.17–8.82)† 293 2.57 (1.62–4.07)*
MMSE 24 to 27 280 2.74 (1.03–7.27)† 430 1.44 (0.94–2.18)
MMSE 28 to 30 101 1 (Reference) 220 1 (Reference)
Adjusted for age, exercise, alcohol consumption, smoking status, education level, marital status, region, body mass index, physical impairment, depression, medical history and
medications by multivariate Cox models. CVD indicates cardiovascular disease; CI, confidence interval; MMSE, Mini-Mental State Examination.
*P<0.001.
†
P<0.05.
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illustrate the stability of the multivariable model for the elderly
population in Beijing and adjusting for a broad range of
potential confounders. Moreover, our study was conducted
among a community-dwelling elderly population with a
generally poor education level and low baseline cognitive
function in Beijing. We explored different adjustment strate-
gies and sensitivity analysis to ensure relatively stable and
reliable results. In addition, we found that each 5-point
decrease in baseline MMSE score increased the risk of all-
cause and CVD mortality. The increased relative risk for all-
cause and CVD mortality reported herein holds potential for
clinical planning and decision making. However, our study
also has some limitations. First, the MMSE is a common
screening instrument, rather than a clinical assessment, and
has limited ability to test executive or visuospatial functions
and detect vascular cognitive dysfunction.23 Second, the
MMSE includes 10 categories representing different domain
items.7 We did not measure the association between different
cognitive domains and mortality. Third, the relationship
between rapid cognitive decline and mortality might differ
among participants whose cognitive function did not decline
or declined slowly. In our study, we only concentrated on
baseline MMSE score and did not explore whether the change
in MMSE score from baseline to follow-up or transitions in
cognitive status are associated with increased risk of all-
cause and CVD mortality. Furthermore, despite that the data
were collected from a large, prospective cohort study in
Beijing, study participants still cannot represent the Chinese
older population. We look forward to the future large-sample
studies in China to confirm the results. Last, although we
were able to adjust for a broad range of covariates, some
potential confounders that were unmeasured or unable to be
fully captured at baseline, such as renal dysfunction,
creatinine clearance, and other residual confounders, might
still not be available in our analysis.
Conclusion
The data from the BLSA indicated that cognitive impairment,
as measured by baseline MMSE score, was associated with an
elevated risk of all-cause and CVD mortality. Our findings
suggest the important value of screening for cognitive
impairment among the elderly. Intervention to maintain high
cognitive function in elderly people is important in reducing
mortality risk, especially with regard to CVD.
Acknowledgments
We sincerely thank those who participated in data collection and
management.
Sources of Funding
The study was supported by The Program of National Natural
Science Foundation of China (Serial No.: 81530087, 81703317).
Disclosures
None.
References
1. Alzheimer’s Disease International. Dementia statistics. 2015. Available at:
https://www.alz.co.uk/research/statistics. Accessed October 29, 2017.
2. Global Burden of Disease Study 2016 (GBD 2016) data resources. 2017.
Available at: http://ghdx.healthdata.org/gbd-2016. Accessed October 29,
2017.
3. Sachs GA, Carter R, Holtz LR, Smith F, Stump TE, Tu W, Callahan CM. Cognitive
impairment: an independent predictor of excess mortality: a cohort study. Ann
Intern Med. 2011;155:300–308.
4. Farid K, Zhang Y, Bachelier D, Gilson P, Teixeira A, Safar ME, Blacher J.
Cognitive impairment and malnutrition, predictors of all-cause mortality in
hospitalized elderly subjects with cardiovascular disease. Arch Cardiovasc Dis.
2013;106:188–195.
5. An R, Liu GG. Cognitive impairment and mortality among the oldest-old
Chinese. Int J Geriatr Psychiatry. 2016;31:1345.
Figure 3. Hazard ratios (95% CI) for cardiovascular disease (CVD) mortality according to baseline Mini-Mental State Examination (MMSE)
score, using competing risks models adjusted for age, sex, exercise, alcohol consumption, smoking status, education level, marital status,
region, body mass index (BMI), physical impairment, depression, medical history, and medications. CI indicates confidence interval.
DOI: 10.1161/JAHA.117.008252 Journal of the American Heart Association 10
Cognitive Impairment and Mortality An et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on October 23, 2018
6. Gao S, Jin Y, Unverzagt FW, Cheng Y, Su L, Wang C, Ma F, Hake AM, Kettler C,
Chen C. Cognitive function, body mass index and mortality in a rural elderly
Chinese cohort. Arch Public Health. 2014;72:9.
7. O’Donnell M, Teo K, Gao P, Anderson C, Sleight P, Dans A, Marzona I, Bosch J,
Probstfield J, Yusuf S. Cognitive impairment and risk of cardiovascular events
and mortality. Eur Heart J. 2012;33:1777–1786.
8. Yano Y, Bakris GL, Inokuchi T, Ohba Y, Tamaki N, Nagata M, Kuwabara M,
Yokota N, Eto T, Kuroki M, Shimada K, Kario K. Association of cognitive
dysfunction with cardiovascular disease events in elderly hypertensive
patients. J Hypertens. 2014;32:423–431.
9. Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F,
Vjecha MJ, Hoy J, Miller C. Cardiovascular risk factors associated with lower
baseline cognitive performance in HIV-positive persons. Neurology.
2010;75:864–873.
10. Melrose RJ, Ettenhofer ML, Harwood D, Achamallah N, Campa O, Mandelkern
M, Sultzer DL. Cerebral metabolism, cognition, and functional abilities in
Alzheimer disease. J Geriatr Psychiatry Neurol. 2011;24:127–134.
11. Abete P, Della-Morte D, Gargiulo G, Basile C, Langellotto A, Galizia G, Testa G,
Canonico V, Bonaduce D, Cacciatore F. Cognitive impairment and cardiovas-
cular diseases in the elderly. A heart-brain continuum hypothesis. Ageing Res
Rev. 2014;18:41–52.
12. Leng X, Espeland MA, Manson JAE, Stefanick ML, Gower EW, Hayden KM,
Limacher MC, Vaughan L, Robinson J, Wallace R. Cognitive function and changes
in cognitive function as predictors of incident cardiovascular disease: the
Women’s Health Initiative Memory Study (WHIMS). J Gerontol. 2017;00:1–7.
13. Batty GD, Deary IJ, Zaninotto P. Association of cognitive function with cause-
specific mortality in middle and older age: follow-up of participants in the
English Longitudinal study of Ageing. Am J Epidemiol. 2016;183:183–190.
14. Georgakis MK, Papadopoulos FC, Protogerou AD, Pagonari I, Sarigianni F,
Biniarisgeorgallis SI, Kalogirou EI, Thomopoulos TP, Kapaki E, Papageorgiou C.
Comorbidity of cognitive impairment and late-life depression increase
mortality: results from a cohort of community-dwelling elderly individuals in
rural Greece. J Geriatr Psychiatry Neurol. 2016;29:195.
15. Perna L, Wahl HW, Mons U, Saum KU, Holleczek B, Brenner H. Cognitive
impairment, all-cause and cause-specific mortality among non-demented older
adults. Age Ageing. 2015;44:445–451.
16. Kerola T, Hiltunen M, Kettunen R, Hartikainen S, Sulkava R, Vuolteenaho O,
Nieminen T. Mini-Mental State Examination score and B-type natriuretic
peptide as predictors of cardiovascular and total mortality in an elderly general
population. Ann Med. 2011;43:650.
17. Liu X, Chen Z, Fine JP, Liu L, Wang A, Guo J, Tao L, Mahara G, Yang K, Zhang J.
A competing-risk-based score for predicting twenty-year risk of incident
diabetes: the Beijing Longitudinal Study of Ageing study. Sci Rep.
2016;6:37248.
18. Shi J, Song X, Yu P, Tang Z, Mitnitski A, Fang X, Rockwood K. Analysis of frailty
and survival from late middle age in the Beijing Longitudinal Study of Aging.
BMC Geriatr. 2011;11:17.
19. Shi J, Yang Z, Song X, Yu P, Fang X, Tang Z, Peng D, Mitnitski A, Rockwood K.
Sex differences in the limit to deficit accumulation in late middle-aged and
older Chinese people: results from the Beijing Longitudinal Study of Aging. J
Gerontol A Biol Sci Med Sci. 2014;69:702–709.
20. Feng L, Chong MS, Lim WS, Ng TP. The Modified Mini-Mental State
Examination test: normative data for Singapore Chinese older adults and its
performance in detecting early cognitive impairment. Singapore Med J.
2012;53:458–462.
21. Sabia S, Gueguen A, Marmot MG, Shipley MJ, Ankri J, Singh-Manoux A. Does
cognition predict mortality in midlife? Results from the Whitehall II cohort
study. Neurobiol Aging. 2010;31:688–695.
22. Matallana D, De SC, Cano C, Reyes P, Samperternent R, Markides KS,
Ottenbacher KJ, Reyesortiz CA. The relationship between education level and
Mini-Mental State Examination domains among older Mexican Americans. J
Geriatr Psychiatry Neurol. 2011;24:9.
23. Woodford HJ, George J. Cognitive assessment in the elderly: a review of clinical
methods. QJM. 2007;100:469–484.
24. Alonso A, Jacobs DR, Menotti A, Nissinen A, Dontas A, Kafatos A, Kromhout D.
Cardiovascular risk factors and dementia mortality: 40 years of follow-up in
the Seven Countries Study. J Neurol Sci. 2009;280:79–83.
25. Drew DA, Weiner DE, Tighiouart H, Scott T, Lou K, Kantor A, Fan L, Strom JA,
Singh AK, Sarnak MJ. Cognitive function and all-cause mortality in mainte-
nance hemodialysis patients. Am J Kidney Dis. 2015;65:303–311.
26. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovas-
cular disease prevention what a difference a decade makes. Circulation.
2011;124:2145.
27. He L, Tang X, Li N, Wu YQ, Wang JW, Li JR, Zhang ZX, Dou HD, Liu JJ, Yu LP.
Menopause with cardiovascular disease and its risk factors among rural
Chinese women in Beijing: a population-based study. Maturitas. 2012;72:132–
138.
28. Schultz-Larsen K, Rahmanfard N, Kreiner S, Avlund K, Holst C. Cognitive
impairment as assessed by a short form of MMSE was predictive of mortality. J
Clin Epidemiol. 2008;61:1227–1233.
29. Peltz CB, Corrada MM, Berlau DJ, Kawas CH. Cognitive impairment in
nondemented oldest-old: prevalence and relationship to cardiovascular risk
factors. Alzheimers Dement. 2012;8:87–94.
DOI: 10.1161/JAHA.117.008252 Journal of the American Heart Association 11
Cognitive Impairment and Mortality An et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on October 23, 2018
  
 
 
SUPPLEMENTAL MATERIAL 
 
D
ow
nloaded from
 http://ahajournals.org by on October 23, 2018
Table S1. Hazard ratios (95% CI) for all-cause and cardiovascular disease mortality 
according to baseline education adjusted MMSE cut-point. 
Cognitive function No. 
All-cause mortality  CVD mortality 
Hazard ratio 
(95% CI) 
P  
value 
 Hazard ratio 
(95% CI) 
P  
value 
Cognitive impairment* 1549 1.30(1.10-1.53) 0.002  1.61(1.23-2.10) <0.001 
Normal cognition 447 Reference  Reference 
*The education adjusted MMSE cut-off scores for cognitive impairment were 25, 27 and 29 
for participants with uneducated, primary school and secondary school or above education 
levels. 
Adjusted for age, sex, exercise, alcohol consumption, smoking status, marital status, region, 
body mass index, education level, activities of daily living, depression, medical history and 
medications by multivariate Cox models.  
CVD, cardiovascular disease; MMSE, Mini-Mental State Examination 
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Table S2. Hazard ratios (95% CI) for all-cause and cardiovascular disease mortality 
according to baseline MMSE score in people without cardiovascular disease (n=1599). 
MMSE score No. 
All-cause mortality  CVD mortality 
Hazard ratio 
(95% CI) 
P  
value 
 Hazard ratio 
(95% CI) 
P  
value 
Decreased by 5 points 1599 1.38(1.24-1.53) <0.001  1.64(1.39-1.94) <0.001 
MMSE <18 163 2.20(1.57-3.07) <0.001  5.02(2.80-8.98) <0.001 
MMSE 18–23 631 1.39(1.06-1.83) 0.018  2.47(1.49-4.10) 0.005 
MMSE 24–27 568 1.09(0.84-1.40) 0.528  1.78(1.10-2.88) 0.019 
MMSE 28–30 237 Reference  Reference 
Adjusted for age, sex, exercise, alcohol consumption, smoking status, marital status, region, 
body mass index, education level, activities of daily living, depression, medical history and 
medications by multivariate Cox models.  
CVD, cardiovascular disease; MMSE, Mini-Mental State Examination 
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